Viewing Study NCT06496373



Ignite Creation Date: 2024-07-17 @ 11:14 AM
Last Modification Date: 2024-10-26 @ 3:34 PM
Study NCT ID: NCT06496373
Status: RECRUITING
Last Update Posted: 2024-07-11
First Post: 2024-06-18

Brief Title: Clinical Study of XP-004 Personalized mRNA Tumor Vaccine Combined With PD-1 Inhibitor for Postoperative Adjuvant Therapy for Pancreatic Cancer in Patients With Advanced Solid Tumors
Sponsor: Ruijin Hospital
Organization: Ruijin Hospital

Study Overview

Official Title: Clinical Study of XP-004 Personalized mRNA Tumor Vaccine Combined With PD-1 Inhibitor for Postoperative Adjuvant Therapy for Pancreatic Cancer in Patients With Advanced Solid Tumors
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main purpose of this study is to observe and evaluate the safety and tolerance of XP-004 personalized mRNA vaccine encoding tumor neoantigen combined with PD-1 inhibitor for adjuvant treatment of patients who cannot tolerate chemotherapy after radical resection of pancreatic cancer

The secondary objective was to observe the initial efficacy of adjuvant therapy with XP-004 personalized mRNA vaccine combined with PD-1 inhibitor in patients with pancreatic cancer after radical surgery by the indicators of XP-004 personalized mRNA vaccine induced activstion of Antigen specific CD4 and CD8 T cells Recurrence free survival RFS and Overall Survival OS
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None